The Cooper Companies, Inc.

The planned sale of CooperSurgical would sharpen Cooper's focus on its high-growth CooperVision contact lens unit. Proceeds are expected to fund substantial share repurchases, with estimates suggesting the stock could be worth $80/share post-divestiture, implying meaningful upside from current levels.

Concerns persist that shedding CooperSurgical removes a meaningful revenue diversification pillar. Goldman Sachs maintains a Sell rating with a price target of $63, well below consensus, suggesting skepticism that the restructuring will generate sufficient value to offset the lost earnings contribution from the surgical segment.

The analyst consensus remains Outperform, with an average 12-month price target of $81.85, implying roughly 12% upside. Citigroup recently raised its price target to $76, and BNP Paribas maintains an Outperform rating, reflecting confidence in Cooper's ability to sustain growth momentum across its core segments.

Growth has materially slowed at The Cooper Companies, prompting multiple downward price target revisions. Rothschild & Co Redburn cut its target from $85 to $78 while maintaining a Neutral rating, and Goldman Sachs reduced its target from $66 to $63, signaling deteriorating near-term earnings visibility.

Positive technical signals have emerged, including the 10-day moving average crossing above the 50-day moving average in June 2026 and the Momentum Indicator moving above zero in July 2026. Historical data shows that in the vast majority of similar past instances, COO continued to climb over the following month.

Competing technical indicators paint a cautionary picture. COO's RSI moved out of overbought territory and the stock broke above its upper Bollinger Band, both historically associated with near-term price pullbacks. Short interest stands at 7.42 million shares, or 3.88% of the float, reflecting meaningful skepticism.